| Diana M. Brainard |
Diana M. Brainard is currently the Chief Executive Officer & Director at AlloVir, Inc., an Independent Director at Nektar Therapeutics, an Independent Director at Affinia Therapeutics, Inc., and an Executive Partner at MPM BioImpact, Inc. Previously, she worked at Gilead Sciences, Inc. as the Senior VP-HIV & Emerging Viral Infections from 2015 to 2021. Dr. Brainard received her undergraduate degree from Brown University in 1992 and her doctorate degree from Tulane University School of Medicine in 1997. |
| Cintia Piccina |
Cintia Piccina is Chief Commercial Officer of AlloVir, Inc.
She previously was Chief Commercial Officer at Adaptimmune Therapeutics Plc and SVP-Commercial Oncology & US General Manager at 2seventy Bio, Inc.
She received a doctorate from the University of Sao Paulo and an MBA from Escola Superior de Propaganda e Marketing. |
| Ercem Atillasoy |
Ercem Atillasoy holds the position of Chief Regulatory & Safety Officer at Viracyte, Inc. He is also Chief Regulatory & Safety Officer at AlloVir, Inc.
In the past Dr. Atillasoy was Vice President of Merck Research Laboratories Massachusetts LLC.
Dr. Atillasoy received an undergraduate degree from City University of New York and an undergraduate degree from Yale School of Medicine. |
| Ann M. Leen |
Ann M. Leen founded AlloVir, Inc. in 2013, where she is working as Chief Scientific Officer from 2013 and Marker Therapeutics, Inc. in 2018, where she worked as Chief Scientific Officer from 2018 to 2020. Dr. Leen also currently works at Science Foundation Ireland, as Director and Baylor College of Medicine, as Professor from 2019. Dr. Leen received her doctorate degree from the University of Birmingham and undergraduate degree from University College Cork. |
| Brett R. Hagen |
Mr. Brett R. Hagen is a Chief Accounting Officer at AlloVir, Inc. Mr. Hagen was previously employed as a Senior Director-Finance & Accounting by Eloxx Pharmaceuticals, Inc., a Chief Accounting Officer & Vice President-Finance by Proteostasis Therapeutics, Inc., a Controller by BIND Therapeutics, Inc., a Vice President-Finance by Boston Private Financial Holdings, Inc., and a Controller by BioProcessors Corp. He received his undergraduate degree from the University of Minnesota, a graduate degree from Wright State University (Ohio) and a graduate degree from Suffolk University. |
| David L. Hallal |
Mr. David L. Hallal is an Executive Chairman at AlloVir, Inc., a Chairman at iTeos Therapeutics SA, a Chairman at iTeos Therapeutics, Inc., a Lead Independent Director at Seer, Inc. (California), a Chairman & Chief Executive Officer at ElevateBio LLC, a Chairman at Scholar Rock, Inc. and a Chairman at Scholar Rock Holding Corp. He is on the Board of Directors at Seer, Inc. (California), LifeEDIT Therapeutics, Inc. and Pharmaceutical Research & Manufacturers of America. Mr. Hallal was previously employed as a Chief Executive Officer & Director by Alexion Pharmaceuticals, Inc., a Vice President-Sales by (OSI) Eyetech, a Head-Sales by Biogen Idec, Inc., a Director-Southeast Oncology Sales by Amgen, Inc., and a Director-National Sales by Oldtech, Inc. He received his undergraduate degree from the University of New Hampshire. |
| Vikas Sinha |
Mr. Vikas Sinha is a President, Chief Financial Officer & Director at AlloVir, Inc., a Chief Financial Officer & Director at ElevateBio LLC, an Independent Non-Executive Director at Verona Pharma Plc and an Associate Member at The Institute of Chartered Accountants of India. He is on the Board of Directors at AlloVir, Inc., ElevateBio LLC, Verona Pharma Plc and LifeEDIT Therapeutics, Inc. Mr. Sinha was previously employed as an Independent Director by BCLS Acquisition Corp., a Chief Financial Officer & Executive Vice President by Alexion Pharmaceuticals, Inc., a Chief Financial Officer & Vice President by Bayer Pharmaceuticals Corp., a Manager-Mergers & Acquisitions by Bayer AG, a Principal by ANZ Banking Corp., and a Chief Financial Officer & Vice President by Bayer Yakuhin Ltd. He received his undergraduate degree from Tribhuvan University and an MBA from Asian Institute of Management. |
| Derek Adams |
Derek Adams is an Independent Director at AlloVir, Inc. He previously served as the President & Chief Executive Officer at Stellular Bio, Inc. in 2022. Prior to that, he was the Senior Vice President-CMC at Evelo Biosciences, Inc. in 2016. From 2015 to 2016, he held the position of VP-Technical & Strategic Product Development at Alexion Pharmaceuticals, Inc. Dr. Adams also served as the Chief Technology & Manufacturing Officer at bluebird bio, Inc. from 2017 to 2021. He holds a doctorate degree from the University of Minnesota and an undergraduate degree from Worcester Polytechnic Institute. |
| Shawn Cline Tomasello |
Ms. Shawn C. Tomasello is an Independent Director at Cabaletta Bio, Inc., an Independent Director at AlloVir, Inc., an Independent Director at 4D Molecular Therapeutics, Inc. and a Chairman at Gamida Cell Ltd. She is on the Board of Directors at Cabaletta Bio, Inc., AlloVir, Inc., 4D Molecular Therapeutics, Inc., Centrexion Therapeutics Corp. and Geneos Therapeutics, Inc. Ms. Tomasello was previously employed as an Independent Director by TCR2 Therapeutics, Inc., an Independent Director by Abeona Therapeutics, Inc., an Independent Non-Executive Director by Mesoblast Ltd., an Independent Director by UroGen Pharma Ltd., a Chief Commercial Officer by Kite Pharma, Inc., an Independent Director by Diplomat Pharmacy, Inc., a Chief Executive Officer by Shawn Tomasello Consulting LLC, a Chief Commercial Officer by Pharmacyclics LLC, a Senior VP, President-Hematology & Oncology by Celgene Corp., a National Director-Hematology by Genentech, Inc., a Trustee by BioNJ, Inc., and a Non-Executive Director by Oxford BioTherapeutics Ltd. She also served on the board at Principia Biopharma, Inc. and Clementia Pharmaceuticals, Inc. She received her undergraduate degree from the University of Cincinnati (Ohio) and an MBA from Murray State University (Kentucky). |
